Partnered Product Pipeline

In its therapeutic antibody collaborations, MorphoSys produces optimized human antibodies for its partners according to their specifications. MorphoSys generates and optimizes the antibodies, whereas the partner is responsible for pre-clinical and clinical development.

Currently, MorphoSys’s partnered product pipeline comprises more than 80 antibody programs. MorphoSys’s list of partners includes a roster of blue-chip biotechnology and pharmaceutical firms, such as Boehringer Ingelheim, Celgene, Daiichi Sankyo, GlaxoSmithKline, Janssen Biotech, Merck & Co., Novartis, Pfizer and Roche.

Indications of Partnered Programs

Indications Partner

Within these partnerships, MorphoSys develops antibodies for the treatment of diseases such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation.


View Full Pipeline

MorphoSys’s portfolio comprises more than 90 antibody development programs.